Interpace Biosciences, Inc.
Morris Corporate Center 1, Building C
300 Interpace Parkway
Parsippany, New Jersey 07054
January 10, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, D.C. 20549
Attn: Tyler Howes
| Re: | Interpace Biosciences, Inc. | |
| Registration Statement on Form S-1 | ||
| SEC File No. 333-261504 | ||
| Filed December 6, 2021, as amended January 3, 2022 and January 7, 2022 |
Ladies and Gentlemen:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Interpace Biosciences, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-261504) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:00 PM, eastern standard time, on January 12, 2022, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Troutman Pepper Hamilton Sanders LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Troutman Pepper Hamilton Sanders LLP, by calling Merrill M. Kraines at (212) 808-2711.
| Interpace Biosciences, Inc. | ||
| By: | /s/ Thomas W. Burnell | |
| Thomas W. Burnell | ||
| President and Chief Executive Officer | ||
| Cc: | Merrill M. Kraines, Troutman Pepper Hamilton Sanders LLP |
